The author makes some really good points. Man...it is so hard to know what to do right now with CD12 interim results so close...if the numbers are really good, SP pops big time, but if not...ugh. I really think overall the numbers will be great, because as the author says, leronlimab works best in s/c patients. I feel like I'm buying more tomorrow after having sold a little bit at $3.20 (family emergency). My average is .86/share, so I'm happy, but even buying 2000 more shares tomorrow with a potential pop to $10 again...come on CYDY...deliver for those who need it medically and for us investors!